Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi): Worried about the remainder of 2019 (?), think nine (9) factors…

April 11, 2019

Volatility, algorithms, sustainability … how are enrollments going as to population and is data from on-going trials being interpreted to render measurable and definitive outcomes? Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019? Why spend time finding sector news and analytics … it’s all right here! 

Regenerative Medicine Earnings Scorecard - Q4/18 and FY18 - to date

March 31, 2019

A scorecard of  (AKA) earnings of 45 covered  companies 44 out of 45 ...   The current LPS (loss per share) or net income, cash positions i.e. "runways" - it's a reflection of this universe's investing "status"  

Sage Therapeutics (SAGE) gets FDA approval for Zulresso, a postpartum depression (severe depression after childbirth) therapy

March 19, 2019

SAGE closed down -$0.78 to $156.10 and is UP +$7.91 or 5.07% to $164.01 in the aftermarket Zulresso is designed to reduce depression symptoms by targeting receptors of the neurotransmitter known as GABA, helping restore the normal balance in the brain that is disrupted around the time of childbirth.

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.